



External Quality Control

A new decade

Piet Meijer
ECAT Foundation
Leiden
The Netherlands



1994

Start of the ECAT Foundation as an independent organisation for external quality assessment in the field of thrombosis.

Thrombophilia module

- Antithrombin
- Protein C
- Protein S
- APC Resistance Testing

Approx. 50 participants in Europe

LABORATORY CODE NUMBER: 101
ECAT FOUNDATION - INTERNATIONAL THROMBOPHILIA EXTERNAL QUALITY ASSESSMENT SCHEME (EQAS) - EXERCISE 96/01


Results:

Antithrombin activity assay (% IU/mL) (Test plasma 96.01)

Your result	Median (n=20)	Range
45.3	45.7	33-61

Protein C activity assay (% IU/mL) (Test plasma 96.02)

Your result	Median	Range
107	100.5 (n=34)	78-132
Protein C antigen	102.0 (n=10)	81.5-117






MAIN PROGRAMME


<u>Description</u>	
Thrombophilia module Antithrombin (activity and antigen), Protein C (activity [chromogenic and clotting] and antigen), Protein S activity, Protein S antigen (total and free), APC Resistance	
Protein C Pathway Test	
Lupus Anticoagulant / Antiphospholipid Antibodies	
D-Dimer	
Coagulation Factor module I (Factor VIII, IX, XI and XII)	
Coagulation Factor module II (Factor II, V, VII and X)	
Von Willebrand Factor module (antigen, activity, collagen binding, multimers, Factor VIII)	
Factor VIII inhibitor ##	
Thrombin Generation Test ##	
HIT – Immunological assays ##	
HIT – Functional assays ##	
Factor XIII	
Fibrinolysis parameters I (Plasminogen, Antiplasmin)	
Fibrinolysis parameters II (t-PA, PAI-1)	
Unfractionated Heparin Monitoring (anti-Xa)	
Low-Molecular Weight heparin Monitoring (anti-Xa)	
Homocysteine	
Post Analytical Platelet Function EQA (electronic survey) \$	
Pre- and post-analytical electronic surveys	



ANTITHROMBIN (% IU/dL)



ANTITHROMBIN	n	mean	CV	range	your result	z-score
Total group	276	32.3	16.1%	16 – 42		
Chromogenic - anti-IIa	169	32.5	15.4%	17 – 42		
Berichrom (Siemens)	64	32.3	13.7%	17 – 40		
Antithrombin Reagent (Siemens)	12	33.3	10.5%	28 – 40		
Stachrom / ATIII (Stago/Roche)	88	32.5	17.0%	17 – 42		
Chromogenic - anti-Xa	107	32.2	17.4%	16 – 42		
Coamatic (Chromogenix)	21	32.3	18.2%	18 – 42		
HemosIL liquid Antithrombin (IL)	42	31.2	17.2%	22 – 42		
Innovance Antithrombin (Siemens)	16	36.5	5.6%	32 – 40		



29 Countries Worldwide




One common approach since 1994

Assessment of analytical performance



LABORATORY SERVICE




“Brain-to-brain information loop”

Lundberg GD, JAMA (1981);245: 1762 - 1763



Laboratory Services





External Quality Assessment

Pre-analytical phase

Analytical phase

Post-analytical phase

Traditional
EQA

Analytical performance



LABORATORY PERFORMANCE ASSESSMENT

Overall lab
performance

Individual
Performance
Indicator

<u>ANTITHROMBIN</u>	n	mean	CV	range	your result	z-score
Total group	248	47.9	10.2%	36 – 64	44	-0.80
Chromogenic - anti-IIa	165	48.4	9.4%	37 – 63	44	-0.98
Berichrom (Dade-Behring)	72	48.3	7.8%	39 – 56		
Stachrom (Stago/Roche)	48	47.8	8.7%	40 – 57	44	-0.90
ATIII (Stago/Roche)	29	50.1	11.2%	40 - 63		

Performance per
assay type

Performance per
method



ANTITHROMBIN


Labcode: 0

Name
Hospital
Department
City
Country

Exercise	Y (Lab Result)	X (Cons. Value)
	0	0
	125	125

2005-1		49.8
2005-2	50.0	45.3
2005-3	118.0	115.3
2005-4	49.0	49.3
2006-1	76.0	74.8
2006-2	119.0	114.1
2006-3	49.0	49.6
2006-4	76.0	74.5
2007-1	97.0	94.9
2007-2	51.0	47.9
2007-3	45.0	44.2
2007-4	63.0	58.8
2008-1	50.0	47.5
2008-2	95.0	94.5
2008-3		
2008-4		

Mean	72.2	68.6
SD		26.1
Number	13.0	



Intercept	1.08	Variability	1.84
Slope	1.01	Corr. Coeff	0.9958

Long-term CV _{analytical}	2.6%
Bias	5.2%



Diagnostic performance

Advanced EQA

Pre-analytical phase

Analytical phase

Post-analytical phase

**Traditional
EQA**

Analytical performance



ISO STANDARD 15189

5.6.4 The laboratory shall participate in interlaboratory comparisons such as those organized by external quality assessment schemes. Laboratory management shall monitor the results of external quality assessment and participate in the implementation of corrective actions when control criteria are not fulfilled.

External quality assessment programmes should, as far as possible, provide clinically relevant challenges that mimic patient samples and have the effect of checking the entire examination process, including pre- and post-examination procedures.



Pre-analytical

CASUS[®] ? Hilfe x Vorschau schliessen

Experte

Clipboard

Zurück

Weiter

Karte 1 von 21 | Plättchenarmes Plasma

Die meisten Gerinnungsparameter werden in plättchenarmem Plasma gemessen. Aber es gibt Ausnahmen – welche?

Aufgabe

Bitte markieren Sie in der folgenden Liste die Parameter, die **nicht** in zellarmem Plasma gemessen werden!

Multiple Choice-Antwort:

Bitte wählen Sie die entsprechende(n) Antwort(en) aus.

- A Faktor XIII
- B Partielle Thromboplastinzeit (PTT)
- C Prothrombinvariante G20210A
- D Thrombozytenaggregation
- E Prothrombin

Abschicken



Bild 1 von 1





Pre-analytical

CASUS[®] ? Hilfe x Beenden


Experte Clipboard ← Zurück → Weiter

Die Bestimmung von Lupus-Antikoagulans erfordert besondere Schritte. Welche der nachstehenden Antworten sind richtig?

Multiple Choice-Antwort: 4 von 7 Antworten sind richtig

Expertenantwort ist in grün dargestellt.

- A Proben für die Bestimmung von Lupus-Antikoagulans sollten zweimal zentrifugiert werden.
- B Proben für die Bestimmung von Lupus-Antikoagulans sollten einmal zentrifugiert werden
- C Die Zentrifugationsgeschwindigkeit sollte optimal 1500 g betragen
- D Die Zentrifugationsgeschwindigkeit sollte optimal 2500 g betragen.
- E Die Zentrifugationszeit sollte 15 Minuten betragen.
- F Die Zentrifugationszeit sollte 5 Minuten betragen.
- G Die Zentrifugation kann bei Raumtemperatur durchgeführt werden.

 1 von 4 Multiple Choice Antworten ist richtig
1 Eintrag wurde zuviel selektiert

Kommentar:
Proben für die Bestimmung von Lupus-Antikoagulans sollten zweimal zentrifugiert werden, um ein plättchenfreies Plasma zu gewährleisten. Die optimale Temperatur bei der Zentrifugation liegt zwischen 15 und 22 Grad °C. Ungekühlte Zentrifugen können bei häufigem Gebrauch zu warm werden und das Probenmaterial überwärmen. Alternativ können Kühlzentrifugen, deren Temperaturbereich zwischen 15 und 22 Grad °C eingestellt wird, benutzt werden.
Die optimale Zentrifugationsgeschwindigkeit liegt bei 1500 g, höhere Geschwindigkeiten können zu Plättchenaktivierung und Lyse der Erythrozyten führen.
Die optimale Zentrifugationsdauer liegt bei 15 Minuten.

Fertig Internet 100%



Pre-analytical

Zusammenfassung Ihrer Fallsitzung

Wollen Sie einen neuen Fall beginnen oder das Programm beenden?

Beenden

Abbrechen

Fallauswahl

Fallenname: Instand-VR-Hämostaseologie

Score: 93%

	Kartename	Kartenkommentar	Antworttyp	Erfolg
1	Antikoagulanzenkunde		Sortier-/Zuordnungsantwort	100%
2	Antikoagulanzen		Sortier-/Zuordnungsantwort	100%
3	Antikoagulanzen als Störfaktoren 1		Multiple Choice-Antwort	
4	Neue Antikoagulanzen		Multiple Choice-Antwort	100%
5	Neue Antikoagulanzen, Wirkungsweise		Multiple Choice-Antwort	66%
6	Neue Antikoagulanzen - Störfaktoren 2		Multiple Choice-Antwort	100%
7	Thrombozytenarmes Plasma - Zentrifugation		Multiple Choice-Antwort	100%
8	Thrombozytenarmes Plasma Zentrifugation Temperatur		Multiple Choice-Antwort	100%
9	Temperaturabhängige Stabilität		Multiple Choice-Antwort	
10	Plasma auftauen		Multiple Choice-Antwort	100%
11	Plättchenarmes Plasma		Multiple Choice-Antwort	
12	Die häufigsten Fehler		Multiple Choice-Antwort	100%
13	Füllungszustand der Röhrchen		Multiple Choice-Antwort	
14	Problem des halbvollen Gerinnungsröhrchens		Multiple Choice-Antwort	100%
15	Ergebnisverfälschung		Multiple Choice-Antwort	100%
16	Qualitätskontrolle		Multiple Choice-Antwort	100%
17	Referenzwerte		Sortier-/Zuordnungsantwort	100%
18	Referenzbereiche		Sortier-/Zuordnungsantwort	67%
19	Probenmaterial für molekulare Diagnostik		Multiple Choice-Antwort	20%
20	Indikationen		Multiple Choice-Antwort	100%
21	Geeignete Methoden		Multiple Choice-Antwort	100%



Post-analytical

Kristoffersen AH *et al Clin Chem* (2006); 52:1871-8.

Postanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare

ANN-HELEN KRISTOFFERSEN,^{1*} GEIR THUE,² and SVERRE SANDBERG^{1,2}

Questionnaire

Patient A is a 72 year-old man, otherwise healthy, who had an operation two years earlier for aortic stenosis with a mechanical heart valve prosthesis. You have taken over his treatment with Marevan (warfarin). During the last months, his INR value have ranged from 3.0 to 3.5. The last result you received was 3.3 INR. His Marevan dosing has been unchanged during this time.


- Give the time in weeks until the next INR measurement:
at least ___ week(s), but not more than ___ weeks.
- If you were to increase his Marevan dose, how low must this INR value be? ___.
- If you were to decrease his Marevan dose, how high must the INR value be? ___.
- In your opinion, what is the therapeutic range for this patient?:
INR value between ___ and ___.




Post-analytical

Results

<u>INR range</u>	Range	10%	25%	50%	75%	90%	CV
Acenocoumarol	0.8 – 2.5	1.0	1.0	1.2	1.6	2.0	28%
Fenprocoumon	0.6 – 2.5	0.9	1.0	1.2	1.6	1.9	30%



Critical Difference




Critical Difference



Case-based EQA

Case description
Test selection
Sample processing
Etc.



Test performance
Performance evaluation
Etc.

Result evaluation
Result interpretation
Etc.



SAMPLES

**ELECTRONIC
QUESTIONNAIRES**

**CASE
STUDY**

**CLINICAL
INFORMATION**

**EDUCATIONAL
RESOURCES**

DIAGNOSTIC PERFORMANCE



- Home
- Information
- Meeting 2010
- CLOT-ED**
- Education
- Calendar
- Corporate Corner
- Terminology
- The Clotting Times
- Links
- Members
- Contact Us

CLOT-ED

CLOT-ED, an educational resource for laboratory professionals with an interest in bleeding and/or thrombotic disorders, was established by Marlies Ledford-Kraemer (Florida, USA) in 2003. In 2010 this educational website became a part of the ECAT Foundation, an External quality Control organization for Assays and Tests in Thrombosis and Haemostasis.

Our name, CLOT-ED, is an acronym. **CLOT** means Coagulation, (fibrino)lysis, Or Thrombosis. **ED** means Education. Our logo depicts coagulation as an amplification process (coagulation enzymes represented by gold ovals) that results in thrombin generation and fibrin formation (formed fibrin clot represented by magenta oval).

Enjoy your learning experience!

CLOT-ED Mission Statement

Our mission is to support and educate laboratory professionals with an interest in haemostasis (coagulation & fibrinolysis) and thrombosis by providing practical and concise information in order to improve the quality of laboratory testing related to these areas.

CLOT-ED Access

The open-access part of the website provide the laboratory professional with general information, interesting links to other websites, a Corporate Corner with information from diagnostic companies, and a meeting Calendar. The limited-access part of the website is for ECAT members and other registered users (annual subscription fee: €50,=) and focuses on the educational aspects of CLOT-ED. If you would like to access this part of CLOT-ED, please use this registration form. To get access to the educational part of CLOT-ED log in [Here](#).





Search Search



ECAT Foundation

External quality Control of diagnostic Assays and Tests

With a focus on thrombosis and haemostasis

- Home
- Information
- Meeting 2010
- CLOT-ED
 - Education
 - Calendar
 - Corporate Corner
 - Terminology
 - The Clotting Times
 - Links
- Members
- Contact Us

Corporate Corner



Highlights of Technoclone are indicated on the next page ...



- Home
- Information
- Meeting 2010
- CLOT-ED**
- Education**
- Educational Topics**
- Focus Articles
- Lab Pointers
- The Clotting Times
- Logout
- Calendar
- Corporate Corner
- Terminology
- The Clotting Times
- Links

- Members
- Contact Us

Educational Topics

Educational Topics are slide presentations for your personal viewing and learning.

- [Activated Partial Thromboplastin Time \(APTT\) Testing Updated 2006](#)
- [ADAMTS-13 Activity and Antigen Assays: Testing for TTP 2007](#)
- [Coagulation Disorders: Coagulation Factors and Their Inhibitors 2006](#)
- Coagulation Pathways
 - [Activation of Platelets by Thrombin 2004](#)
 - [Activation of Protein C by Thrombin 2004](#)
 - [Activation of TAFI by Thrombin 2004](#)
 - [Coagulation Pathways \(All Components\) 2004](#)
 - [Fibrinolytic Pathway 2004](#)
 - [Intrinsic Pathway-APTT 2004](#)
 - [Tissue Factor Pathway \(Extrinsic\) with Common Pathway \(PT\) 2004](#)
- [Factor VIII Activity Assays 2006](#)
- [Hemostasis Principles 2006](#)
- [Laboratory Diagnosis of the Lupus Anticoagulant \(Antiphospholipid Antibodies\) 2006](#)
- [Mixing it Up with APTT and PT Mixing Studies Updated 2006](#)
- [Platelets: Structure/Function, Testing, and Pharmacologic Inhibition 2006](#)
- [Prothrombin Time Testing Updated 2006](#)
- [Six Sigma Management: A Tool for Implementing ISO 15189:2003 2006](#)
- [Von Willebrand Factor Functional Assays 2006](#)
- [Von Willebrand Factor \(VWF\) Testing 2006](#)





External Quality Control in the New Decade:

- New challenges
- Analytical Performance / Diagnostic Performance
- Education
- Workshops
- ???

To work with you together on further quality improvement in the haemostasis laboratory!



THANK YOU FOR YOUR ATTENTION